Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
IRWD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.53 - $5.13
Previous CloseN/A
Volume359.32K
Average Volume (3M)1.43M
Market Cap
$212.79M
Enterprise Value$632.64M
Total Cash (Recent Filing)$92.85M
Total Debt (Recent Filing)$598.67M
Price to Earnings (P/E)85.7
Beta0.66
Next Earnings
Nov 06, 2025EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding162,434,130
10 Day Avg. Volume1,317,340
30 Day Avg. Volume1,428,427
Financial Highlights & Ratios
PEG Ratio-8.00
Price to Book (P/B)-2.34
Price to Sales (P/S)2.01
P/FCF Ratio6.82
Enterprise Value/Market Cap2.97
Enterprise Value/Revenue2.05
Enterprise Value/Gross Profit2.28
Enterprise Value/Ebitda7.91
Forecast
1Y Price Target
$1.00Price Target Upside-21.88% Downside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Earnings GuidanceManagement expects the rest of the year to show similar strength as 2Q, with guidance for $260-290M total revenue and adjusted EBITDA greater than $105M reiterated.
Revenue GrowthPrescription demand growth continues to be strong with IRWD highlighting 8% y/y volume growth in 1Q25.
Bears Say
Debt And Financial UncertaintyThe high debt load and delay in apraglutide's revenue contribution mean there will likely be no meaningful revenue contribution until after Linzess' loss of exclusivity and debt maturity.
Regulatory ChallengesThe FDA requires another confirmatory Phase 3 trial for Apraglutide to validate its efficacy and match previous exposure levels.
Ironwood Pharma News
IRWD FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Ironwood Pharma lowest stock price was $0.53 and its highest was $5.13 in the past 12 months.
What is Ironwood Pharma’s market cap?
Ironwood Pharma’s market cap is $212.79M.
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is Nov 06, 2025 which is in 51 days.
How were Ironwood Pharma’s earnings last quarter?
Ironwood Pharma released its earnings results on Aug 07, 2025. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.023 by $0.117.
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Overvalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma does not currently pay dividends.
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate is 0.11.
How many shares outstanding does Ironwood Pharma have?
Ironwood Pharma has 162,434,130 shares outstanding.
What happened to Ironwood Pharma’s price movement after its last earnings report?
Ironwood Pharma reported an EPS of $0.14 in its last earnings report, beating expectations of $0.023. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Ironwood Pharma?
Currently, no hedge funds are holding shares in IRWD
Ironwood Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (-21.88% Downside)
$1.00 (-21.88% Downside)
Blogger Sentiment
Bullish
IRWD Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 115.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.08%
12-Months-Change
Fundamentals
Return on Equity
-8.02%
Trailing 12-Months
Asset Growth
-13.31%
Trailing 12-Months
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
IRWD Stock 12 Month Forecast
Average Price Target
$1.00
▼(-21.88% Downside)
Technical Analysis
Assertio Therapeutics
―
Esperion
―
Cumberland Pharmaceuticals
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
13.70% Insiders
14.84% Mutual Funds
29.89% Other Institutional Investors
25.42% Public Companies and
Individual Investors